© 2005 European Society of Cardiology
The value of B-type natriuretic peptide and big endothelin-1 for detection of severe pulmonary hypertension in heart transplant candidates
Kubáneka,*
ra Lánskác
a Department of Cardiology, Institute for Clinical and Experimental Medicine Vide
ská 1958/9, Prague 140 21, Czech Republic
b Department of Clinical Chemistry, Institute for Clinical and Experimental Medicine Prague, Czech Republic
c Department of Medical Statistics, Institute for Clinical and Experimental Medicine Prague, Czech Republic
* Corresponding author. Fax: +42 4024728225. E-mail address: mikb{at}medicon.cz
 |
Abstract |
|---|
Background: Severe pulmonary hypertension (PH) and increased pulmonary vascular resistance (PVR) are important risk factors that predict early postoperative mortality after orthotopic heart transplantation. The aim of our study was to determine the value of B-type natriuretic peptide (BNP) and big endothelin-1 (big ET1) for prediction of severe PH in heart transplant candidates.
Methods: The study population included 43 potential heart transplant candidates (38 males, mean age 52±7 years). All underwent repeated right-heart catheterizations (2–5 studies) at an interval of 3–4 months, giving a total of 124 examinations, associated with blood sampling for BNP and big ET1 analysis. Severe PH was defined as the mean pulmonary artery pressure (MPAP)>40 mmHg.
Results: Significantly high PVR (PVR>3.0 Wood units and TPG>15 mmHg) was noted on 12 occasions in 10 patients; always in the presence of severe PH. Low BNP levels (<67 pg/ml) ruled out the presence of severe PH with a 100% sensitivity, however, with a low specificity (34%). An increase in plasma BNP>30 pg/ml (>40% of initial value) in subjects with a previous MPAP–40 mmHg detected development of severe PH with a 100% sensitivity and an 80–88% specificity. As a total of 58% of patients presented repeatedly with MPAP
40mmHg, serial BNP testing could reduce the need for hemodynamic studies in this subgroup down to 12–20%.
Conclusions: Serial BNP testing in hemodynamically stable heart transplant candidates with MPAP–40 mmHg allows reliable detection of development of severe PH, and may significantly reduce the need for repeated right-heart catheterizations in these patients.
Key Words: B-type natriuretic peptide • Big endothelin-1 • Congestive heart failure • Pulmonary hypertension • Orthotopic heart transplantation
Received April 13, 2004; Revised October 12, 2004; Accepted December 20, 2004
* This study was funded by the grant of the Ministry of Health of the Czech republic No:VZ IKEM: CEZ L 17/98: 00023001.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kubanek, I. Malek, J. Bytesnik, P. Fridl, L. Riedlbauchova, L. Karasova, V. Lanska, and J. Kautzner Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months Eur J Heart Fail, December 1, 2006; 8(8): 832 - 840. [Abstract] [Full Text] [PDF]
|
|